[{"orgOrder":0,"company":"Adimab","sponsor":"Ablexis","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Antibody","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Adimab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Adimab \/ Ablexis","highestDevelopmentStatusID":"3","companyTruncated":"Adimab \/ Ablexis"},{"orgOrder":0,"company":"Adimab","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Adimab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adimab \/ Ono Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Adimab \/ Ono Pharmaceutical"}]

Find Clinical Drug Pipeline Developments & Deals by Adimab

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, Adimab will discover novel therapeutic antibodies against multiple targets selected by Ono and generate bispecific antibody product candidates. Ono will evaluate and develop such candidates at the pre-clinical and clinic...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 27, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Ono Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : The non-exclusive license grants Adimab rights to implement select strains of AlivaMab Mouse into its proprietary yeast-based technology for antibody drug discovery for its clients.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          February 09, 2023

                          Lead Product(s) : Antibody

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Ablexis

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank